| Bid | 23.06 |
| Market Cap | 2.54B |
| Revenue (ttm) | - |
| Net Income (ttm) | - |
| EPS (ttm) | -2.21 |
| PE Ratio (ttm) | -10.75 |
| Forward PE | n/a |
| Analyst | Buy |
| Ask | 32.62 |
| Volume | 431,311 |
| Avg. Volume (20D) | 803,177 |
| Open | 24.68 |
| Previous Close | 24.58 |
| Day's Range | 23.76 - 24.79 |
| 52-Week Range | 15.19 - 27.29 |
| Beta | undefined |
About NAMS
NewAmsterdam Pharma Company N.V., a clinical-stage biopharmaceutical company, focuses on improving patient care in populations with metabolic diseases. Its lead investigational candidate, obicetrapib, is a novel, selective inhibitor that targets the Cholesteryl Ester Transfer Protein (CETP), which has been clinically shown to reduce low-density lipoprotein cholesterol (LDL-C) while at the same time substantially increase high-density lipoprotein ...
Analyst Forecast
According to 7 analyst ratings, the average rating for NAMS stock is "Buy." The 12-month stock price forecast is $36.5, which is an increase of 53.59% from the latest price.
1 month ago · seekingalpha.com
NewAmsterdam Pharma: Positive Obicetrapib Data Leads To New CatalystsNewAmsterdam Pharma Company N.V.'s drug obicetrapib achieved positive results in phase 3 BROADWAY study, significantly reducing LDL-C in ASCVD and HeFH patients when added to statins. Positive data en...
